Sugi Predict

Sugi Predict / Compounds / SCHEMBL9955206

SCHEMBL9955206

SCHEMBL9955206

Cc1ccc(-c2ccccn2)c(C(=O)O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.47
▸ KDM4C Q9H3R0 2/20 0.47
▸ KDM6B O15054 1/20 0.47
▸ KDM4A O75164 1/20 0.47
▸ KDM5C P41229 1/20 0.47
▸ KDM2A Q9Y2K7 1/20 0.47
▸ KDM3A Q9Y4C1 1/20 0.47
▸ BTK Q06187 1/20 0.47
▸ CSNK2A1 P68400 1/20 0.46
▸ DHODH Q02127 4/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ HTT P42858 1/20 0.45
▸ KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29814525 1.00 KDM4E (0.47) KDM4EKDM4CKDM6BKDM4AKDM5C
SCHEMBL27870871 0.89 BTK (0.48) KDM4EBTKALDH1A1HSD17B10NPC1
SCHEMBL19499711 0.88 BRD4 (0.50) KDM4EKDM4CBTKALDH1A1HSD17B10
SCHEMBL22468515 0.88 KDM4E (0.47) KDM4EKDM4CKDM6BKDM4AKDM5C
SCHEMBL9955328 0.84 CYP46A1 (0.63) KDM4EBTKALDH1A1HSD17B10PKM
SCHEMBL17427074 0.83 KDM4E (0.56) KDM4EKDM4CKDM6BKDM4AKDM5C
SCHEMBL29693869 0.83 TTR (0.47) KDM4EKDM4CKDM6BKDM4AKDM5C
SCHEMBL28217365 0.83 KDM4E (0.61) KDM4EKDM4CKDM6BKDM4AKDM5C
SCHEMBL29683512 0.82 CSNK2A1 (0.50) KDM4ECSNK2A1DHODHALDH1A1TP53
SCHEMBL607770 0.82 CSNK2A1 (0.50) KDM4ECSNK2A1DHODHALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040966-B2 Benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2021-06-22 — — US disclosed
US-11040966-B2 Benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2021-06-22 — — US disclosed
US-10787432-B2 N-[(pyridyloxy)propanyl]benzamides BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-09-29 — — US disclosed
US-10787432-B2 N-[(pyridyloxy)propanyl]benzamides BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-09-29 — — US disclosed
WO-2020099511-A1 BENZIMIDAZOLE-2-METHYL-MORPHOLINE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2020-05-22 — — WO disclosed
EP-3442958-B1 NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES BOEHRINGER INGELHEIM INT (DE) 2020-05-06 — — EP disclosed
EP-3442958-B1 NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES BOEHRINGER INGELHEIM INT (DE) 2020-05-06 — — EP disclosed
WO-2020007977-A1 7-TRIFLUOROMETHYL-[1,4]DIAZEPAN DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2020-01-09 — — WO disclosed
WO-2020007964-A1 2-(2-AZABICYCLO[3.1.0]HEXAN-1-YL)-1H-BENZIMIDAZOLE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2020-01-09 — — WO disclosed
US-20190263797-A1 BENZIMIDAZOLE-PROLINE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2019-08-29 — — US disclosed
WO-2013182972-A1 BENZIMIDAZOLE-PROLINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-12-12 — — WO disclosed
EP-2670745-A1 SPIRO AMINIC COMPOUNDS WITH NK1 ANTAGONIST ACTIVITY Rottapharm S.p.A. (IT) 2013-12-11 — — EP disclosed
US-20130310400-A1 SPIRO AMINIC COMPOUNDS WITH NK1 ANTAGONIST ACTIVITY ROTTAPHARM S.P.A. (IT) 2013-11-21 — — US disclosed
WO-2013050938-A1 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-04-11 — — WO disclosed
WO-2012104338-A1 SPIRO AMINIC COMPOUNDS WITH NK1 ANTAGONIST ACTIVITY ROTTAPHARM S.P.A. (IT) 2012-08-09 — — WO disclosed
EP-2484674-A1 Spiro aminic compounds with NK1 antagonist activity ROTTAPHARM S.P.A. (IT) 2012-08-08 — — EP disclosed
WO-2012085857-A1 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES ACTELION PHARMACEUTICALS LTD (CH) 2012-06-28 — — WO disclosed
WO-2012085852-A1 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES ACTELION PHARMACEUTICALS LTD (CH) 2012-06-28 — — WO disclosed
WO-2012085852-A1 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES ACTELION PHARMACEUTICALS LTD (CH) 2012-06-28 — — WO disclosed
WO-2012085857-A1 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES ACTELION PHARMACEUTICALS LTD (CH) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10787432-B2 N-[(pyridyloxy)propanyl]benzamides HCRTR1, HCRTR2, CNR1 KDM4E 1759/4885KDM4C 2006/4885KDM6B 2116/4885
US-20130310400-A1 SPIRO AMINIC COMPOUNDS WITH NK1 ANTAGONIST ACTIVITY TACR2, TACR1, TAC3 KDM4E 2409/4885KDM4C 2650/4885KDM6B 2843/4885
US-11040966-B2 Benzimidazole-proline derivatives HCRTR1, HCRTR2, NPY1R KDM4E 2320/4885KDM4C 2986/4885KDM6B 2499/4885
US-20190263797-A1 BENZIMIDAZOLE-PROLINE DERIVATIVES HCRTR1, HCRTR2, NPY1R KDM4E 2320/4885KDM4C 2986/4885KDM6B 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.